Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Catabasis Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Catabasis Pharmaceuticals is a U.S. public bio/pharmaceutical company that focuses on the discovery and development of drugs to treat inflammatory and metabolic conditions. It has raised $11.5 million in a secondary public offering, as reported in the PharmSource Lead Sheet on September 29, 2016.

Corporate Highlights

  • Catabasis Pharmaceuticals was incorporated in Delaware in 2008
  • Corporate Headquarters: Cambridge, MA – approximately 19,000 square feet of office and laboratory space
  • As of March 15, 2016, they had 37 employees
  • Stock Exchange: NASDAQ
  • Stock Symbol: CATB

Sourcing Opportunities

  • Catabasis Pharmaceuticals plans to use the proceeds to fund clinical trials with CAT-1004, for market development activities and for R&D of its preclinical pipeline.
    • CAT-1004 – To complete a Phase II study:
      • For treatment of Duchenne muscular dystrophy
      • Dosage Form: Capsule – Soft gelatin
      • Nature of API: Chemical – Normal potency
      • Therapeutic Area: Pediatric; Muscular/Musculoskeletal
    • CAT-4001 – To complete preclinical studies:
      • For treatment of ALS and Friedreich’s ataxia
      • Dosage Form: Unknown
      • Nature of API: Chemical – Normal potency
      • Therapeutic Area: Muscular/Musculoskeletal; Neurology/CNS
  • The company relies on contract research organizations (CROs) and clinical investigators to conduct clinical trials.
  • Catabasis Pharmaceuticals does not own or operate manufacturing facilities and relies on third party contract manufacturers for all required raw materials, API and finished product for preclinical studies and clinical trials.
  • Catabasis Pharmaceuticals has no sales, marketing or distribution infrastructure or experience.

Business Relationships

  • In September 2016, Catabasis Pharmaceuticals and Sarepta Therapeutics entered into a research collaboration agreement for the combination of CAT-1004 with an exon skipping treatment developed by Sarepta for the treatment of Duchenne Muscular Dystrophy. Financial terms were undisclosed.1

Drug Product Pipeline

Product Candidate Indication Dosage Form Status Next Anticipated Step
SMART linker small molecule conjugate Rare disease Unknown Discovery Initiate preclinical activities
CAT-4001 Friedreich’s ataxia/ALS Unknown Preclinical Complete preclinical activities
CAT-1004 Duchenne muscular dystrophy Capsule – Soft gelatin Phase II Results expected in late 2016

Finances

(In $ thousands) 2015 2014
Revenues
R&D Expenditures
23,030
15,686
General & Administrative Expenditures
8,629
5,995
Total Operating Expenses
31,659
21,681

1Catabasis Pharmaceuticals, Inc. 3/15/16 10-K, SEC.gov

Contact Information

Catabasis Pharmaceuticals, Inc. Key Officers
One Kendall Square, Bldg. 1400E, Suite B14202 Jill C. Milne, CEO
Cambridge, MA 02139 USA Andre Nichols, PhD, SVP, Research & Non-Clinical Development
Phone: +1-617-349-1971 Joanne M. Donovan, MD, PhD, CMO
Fax: +1-617-273-2637 Maria Mancini, Senior Director, Clinical Operations
Web: www.catabasis.com Joseph Johnston, VP, Regulatory Affairs

Related posts:
Follow the Money to Pharmaceutical Opportunities – Spotlight on OncoMed Pharmaceuticals, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on Galena Biopharma, Inc.
Follow the Money to Pharmaceutical Opportunities – Spotlight on Medgenics, Inc.

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu